Concept
Mutant Receptors
Share your story with the Oxford-Harrington Rare Disease Centre / Targeting Spinal and Bulbar Muscular Atrophy
"Professor Carlo Rinaldi, 2024 Oxford-Harrington Rare Disease Scholar, is developing a therapy to target mutant androgen receptors in spinal and bulbar muscular atrophy."
Related Ideas
- Myeloid AgonistNature · Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism
- Target IdentificationFuture of Cancer Science | AACR Cancer Progress Report 2025 · Advancing New Treatments
- RLT BasicsFuture of Cancer Science | AACR Cancer Progress Report 2025 · Radiopharmaceutical Therapy
- AI DevelopmentFuture of Cancer Science | AACR Cancer Progress Report 2025 · Advancing New Treatments
- Drug DevelopmentFuture of Cancer Science | AACR Cancer Progress Report 2025 · Drug Development
- Gene EditingFuture of Cancer Science | AACR Cancer Progress Report 2025 · Next-Generation Treatments
- Targeted DeliveryFuture of Cancer Science | AACR Cancer Progress Report 2025 · Next-Generation Treatments
- Immune ReprogrammingFuture of Cancer Science | AACR Cancer Progress Report 2025 · Next-Generation Treatments